Newfeed

Highlights from the Data Presentation Initial safety data presented on the first 10 chronically HBV-infected patients representing 674 patient days of treatmentVRON-0200 was well tolerated, with no serious adverse events (SAEs) observed:no patients discontinued treatmentone treatment related advers

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: